Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.2752W HIGH $9.94
Volume
978.91 K
Value Traded
9.91 M
Short % Float
14.85%
-2.16%Week
-13.71%1 Month
-27.4%3 Month
-37.26%6 Month
-66.92%5 Year
-35.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
273.90 M
EPS (TTM)
-4.55
P/E Ratio
-
Ent. Value
103.87 M
Total Shares
60.43 M
Float Shares
57.20 M
Insiders
5.40%
Institutions
85.54%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VNDA Catalyst Timeline
Dated clinical, regulatory and corporate events for Vanda Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vanda Pharmaceuticals Inc.
826Total events
19Upcoming
266Tier-1 (high impact)
2010 to 2038Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationImsidolimabFiledPresentation
Poster P1769: Rapid reduction in neutrophils and neutrophil percentage-to-albumin ratio upon treatment with imsidolimab in patients with GPP
Generalized Pustular Psoriasis (GPP)source ↗
▲Secondary Endpoint DataHETLIOZApprovedClinical Data
Exploratory responder analysis: 60% of tasimelteon-treated participants advanced sleep timing by at least 30 minutes
Delayed Sleep-Wake Phase Disorder (DSWPD)source ↗
●Safety Data UpdateHETLIOZApprovedClinical Data
No new safety signals identified over 28-day controlled period
Delayed Sleep-Wake Phase Disorder (DSWPD)source ↗
▲Primary Endpoint MetHETLIOZApprovedClinical Data
Phase III study met primary endpoint of sleep onset timing change
Delayed Sleep-Wake Phase Disorder (DSWPD)source ↗
▲Topline ReadoutHETLIOZApprovedClinical Data
Positive Phase III topline results of HETLIOZ 20 mg in DSWPD
Delayed Sleep-Wake Phase Disorder (DSWPD)source ↗
▲Additional DataHETLIOZApprovedClinical Data
Exploratory responder analysis: 60% of tasimelteon-treated participants advanced sleep timing by at least 30 minutes
Delayed Sleep-Wake Phase Disorder (DSWPD)source ↗
▲EU Orphan DesignationImsidolimabFiledEx-US Regulatory
European Commission grants Orphan Designation for imsidolimab for GPP
Generalized Pustular Psoriasissource ↗
▲CHMP Positive OpinionImsidolimabFiledEx-US Regulatory
EMA CHMP positive opinion for orphan drug designation of imsidolimab for GPP
generalized pustular psoriasissource ↗
▲FDA ApprovalNEREUSApprovedFDA Decision
FDA approval of NEREUS for prevention of vomiting induced by motion
prevention of vomiting induced by motionsource ↗
▲Rare Pediatric DiseaseVCA-894ADesignation
FDA grants Rare Pediatric Disease Designation to VCA-894A for CMT2S
Charcot-Marie-Tooth disease type 2Ssource ↗
▲EU Orphan DesignationQuimilzaEx-US Regulatory
EMA COMP positive opinion for orphan drug designation for Quimilza
Generalized Pustular Psoriasis (GPP)source ↗
▲Rare Pediatric DiseaseVCA-894ADesignation
FDA granted Rare Pediatric Disease Designation to VCA-894A
Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S)source ↗
◆FDA ApprovalImsidolimabFiledFDA Decision
Potential FDA approval of imsidolimab for GPP
generalized pustular psoriasissource ↗
▲Other Regulator MilestoneImsidolimabFiledEx-US Regulatory
MHLW grants orphan drug designation to imsidolimab for GPP
generalized pustular psoriasissource ↗
◆Oral PresentationPresentation
Vanda participates at B. Riley Securities 26th Annual Investor Conference
◆Oral PresentationPresentation
Vanda participates at HCW 4th Annual BioConnect Investor Conference fireside chat
◆Oral PresentationPresentation
Vanda participates at Bank of America Securities Global Health Care Conference 2026
◆Quarterly UpdateCorporate
Conference call to discuss Q1 2026 financial results and corporate activities
▲FDA ApprovalBYSANTIApprovedFDA Decision
FDA approval of BYSANTI
bipolar I disorder and schizophreniasource ↗
▲Product LaunchNEREUSApprovedPost-Market
U.S. commercial availability of NEREUS (tradipitant) for motion sickness
prevention of vomiting induced by motion in adultssource ↗
▲Product LaunchNEREUSApprovedPost-Market
U.S. commercial availability of NEREUS (tradipitant) for motion sickness
prevention of vomiting induced by motion in adultssource ↗
▲Orphan Drug DesignationQuimilzaDesignation
Japan MHLW granted orphan drug designation to Quimilza
Generalized Pustular Psoriasis (GPP)source ↗
▲PublicationImsidolimabFiledPresentation
Publication of 'Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis' in NEJM Evidence
Generalized Pustular Psoriasissource ↗
▲Trial InitiationNEREUSApprovedTrial
Initiation of Thetis study evaluating NEREUS for GLP-1-induced vomiting
prevention of vomiting induced by GLP-1 receptor agonistssource ↗
▲Product LaunchNEREUSApprovedPost-Market
NEREUS became commercially available in Q2 2026
prevention of vomiting induced by motionsource ↗
◆Oral PresentationPresentation
Corporate presentation at 2026 Citizens Life Sciences Conference
▲FDA Feedback ReceivedHETLIOZApprovedFDA Meeting
FDA grants formal evidentiary public hearing for HETLIOZ sNDA in jet lag disorder
jet lag disordersource ↗
▲Product LaunchNEREUSApprovedPost-Market
U.S. launch of NEREUS
prevention of vomiting induced by motionsource ↗
▲FDA Filing AcceptedImsidolimabFiledRegulatory Filing
FDA accepted BLA filing for imsidolimab
Generalized Pustular Psoriasissource ↗
◆PDUFA DateBYSANTIApprovedRegulatory Filing
PDUFA target action date for Bysanti NDA for bipolar I disorder and schizophrenia
bipolar I disorder and schizophreniasource ↗
◆FDA ApprovalBYSANTIApprovedFDA Decision
Potential FDA approval of Bysanti
bipolar I manic and mixed episodes and schizophreniasource ↗
▲FDA ApprovalBYSANTIApprovedFDA Decision
FDA approval of BYSANTI for acute treatment of manic/mixed episodes in bipolar I disorder and schizophrenia
Bipolar I Disorder and Schizophreniasource ↗
▲FDA ApprovalNEREUSApprovedFDA Decision
FDA approval of NEREUS (tradipitant) for motion-induced vomiting prevention
motion-induced vomiting preventionsource ↗
▼Complete Response LetterHETLIOZApprovedFDA Decision
FDA issued decision letter concluding sNDA for HETLIOZ in jet lag disorder cannot be approved in current form
jet lag disordersource ↗
◆FDA Feedback ReceivedHETLIOZApprovedFDA Meeting
FDA expedited re-review of sNDA for HETLIOZ for jet lag disorder
jet lag disordersource ↗
◆Trial InitiationNEREUSApprovedTrial
Start Phase III program for NEREUS in GLP-1 analog-induced vomiting prevention
prevention of vomiting from GLP-1 analogssource ↗
◆Trial InitiationTradipitantApprovedTrial
Phase 3 program anticipated to initiate in first half of 2026
prevention of GLP-1 induced nausea and vomitingsource ↗
◆IP Litigation RulingHETLIOZApprovedIP / Competition
Jury trial for HETLIOZ patent litigation scheduled
▲FDA ApprovalBYSANTIApprovedFDA Decision
FDA approval of BYSANTI for bipolar I disorder and schizophrenia
bipolar I disorder and schizophreniasource ↗
▲FDA ApprovalNEREUSApprovedFDA Decision
FDA approval of NEREUS (tradipitant) for motion sickness
prevention of vomiting induced by motion in adultssource ↗
◆PDUFA DateTradipitantApprovedRegulatory Filing
PDUFA target action date for tradipitant NDA for motion sickness
motion sicknesssource ↗
●BLA SubmissionImsidolimabFiledRegulatory Filing
BLA submission to FDA for imsidolimab for GPP
generalized pustular psoriasissource ↗
◆Priority ReviewImsidolimabFiledRegulatory Filing
Priority review requested for imsidolimab BLA
generalized pustular psoriasissource ↗
▲Topline ReadoutImsidolimabFiledClinical Data
Positive topline results from GEMINI-2 maintenance study
generalized pustular psoriasissource ↗
◆Partial Clinical HoldTradipitantApprovedIND
Partial clinical hold re-review target completion date extended to December 5, 2025
motion sicknesssource ↗
Past FDA Catalysts and PDUFA Decisions
How VNDA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-20 | Bysanti™ | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B61 / 100
Pipeline Score
$738M
Pipeline Value
$216M
Commercial Value
Undervalued
Valuation Signal
11
Drugs Scored
8.8x
rNPV / MCap
Top 6%
Micro Cap(rank 40 of 658)
Percentile Rank
Vanda Pharmaceuticals Inc. holds a solid B-grade pipeline (61/100), with $3.9B risk-adjusted pipeline value, led by Imsidolimab in Generalized Pustular Psoriasis (Phase 3), across $98B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $215.7M x 1.0 = $216M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Fanapt | $130M | $103M | +25.7% |
| HETLIOZ | $56M | $75M | -25.5% |
| PONVORY | $29M | $25M | +14.8% |
| NEREUS | $1M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Imsidolimab Monoclonal antibodyCompletedNCT03619902 | Generalized Pustular Psoriasis | Phase 3 | COMPLETED | 53 | Jan 20, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every VNDA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HETLIOZ | Delayed Sleep-Wake Phase Disorder | Phase 3 | 2026-09-29 | primary endpoint change: 37.1 minutes; percentage shifted sleep: 60%; placebo percentage shifted sleep: 15%; p value primary: 0.022; p value secondary: 0.008Read More | Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase DisorderRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mitchell Stephen RayDirector | Disposition | -25,836 71,246 held | $0.00 | 05/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VNDA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 2.7 % (-15.6 %) | 7.22 M | 1.18 M |
VNDA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VNDA ranks across every disease it competes in
Competitive Position is a premium feature
See how VNDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVNDA News
VNDAVanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
Vanda Pharmaceuticals announced its participation in the EADV Annual Meeting in Vienna, where it will present multiple studies on imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The presentations include data on neutrophil reduction and immunogenicity of the drug. Vanda holds exclusive rights for imsidolimab, which is expected to have regulatory and patent exclusivity until the late 2030s.
Read more →VNDAVanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
Vanda Pharmaceuticals announced positive Phase III results for HETLIOZ® (tasimelteon) in treating Delayed Sleep-Wake Phase Disorder (DSWPD). The study demonstrated a significant shift in sleep onset timing, with 60% of treated participants advancing their sleep by at least 30 minutes. Vanda plans to submit a supplemental New Drug Application to the FDA for this new indication.
Read more →VNDAVanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals has announced its participation in several investor conferences scheduled for September 2026. The company will present at the Wells Fargo 21st Annual Healthcare Conference and the Cantor Global Healthcare Conference, among others. These events provide Vanda an opportunity to connect with investors and discuss its innovative therapies.
Read more →VNDAVanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
Vanda Pharmaceuticals announced that its investigational drug, imsidolimab, has received Orphan Designation from the European Commission for the treatment of Generalized Pustular Psoriasis (GPP). This designation is significant as it marks the first recognition of a drug for GPP treatment in the EU. Imsidolimab has also been granted orphan status in the US and Japan, and its Biologics License Application is under FDA review.
Read more →VNDANEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Vanda Pharmaceuticals announced its sponsorship of the NEREUS™ No. 47 IndyCar, driven by Mick Schumacher, for the inaugural Freedom 250 Grand Prix in Washington, D.C. The event, celebrating America's 250th anniversary, features a temporary street circuit on the National Mall. NEREUS™ is the first new medication approved for motion-induced vomiting in 47 years, aligning with the company's focus on performance.
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda Pharmaceuticals reported its second quarter 2026 financial results, highlighting a 23% increase in Fanapt sales and FDA approval for BYSANTI. Despite a 4% decline in total net product sales and a significant loss before taxes, the company maintains a positive outlook with expected revenue guidance of $240-$290 million for the year. The commercial launch of NEREUS is anticipated to further enhance growth.
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Vanda Pharmaceuticals Inc. will announce its second quarter 2026 financial results on August 5, 2026, after market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate activities. The call will be accessible via phone and streamed on Vanda's website.
Read more →VNDAVanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
Vanda Pharmaceuticals announced that the EMA has adopted a positive opinion for orphan drug designation of imsidolimab for generalized pustular psoriasis (GPP). This is the first time GPP has been recognized as an orphan disease in the EU, highlighting the urgent need for effective treatments. The drug targets the IL-36 signaling pathway, addressing a critical deficiency in GPP patients. The designation follows similar recognitions in the U.S. and Japan, with the FDA currently reviewing the Biologics License Application.
Read more →VNDA▼ -6.8%on this newsshared move
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
Vanda Pharmaceuticals announced the sponsorship of the No. 47 IndyCar entry with Rahal Letterman Lanigan Racing, celebrating the launch of NEREUS™ (tradipitant), the first new motion sickness treatment in 47 years. This partnership highlights the significance of NEREUS™ as a breakthrough in motion sickness prevention, aligning with the high-speed demands of IndyCar racing. The NEREUS™-branded car will feature visibility in select events throughout the 2026 season.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
Vanda Pharmaceuticals Inc. has announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, scheduled for July 16, 2026, in Boston, Massachusetts. This event will feature a fireside chat, showcasing Vanda's commitment to innovative therapies. The company aims to address significant medical needs and improve patient lives.
Read more →VNDAVanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals has received FDA Rare Pediatric Disease Designation for its investigational therapy VCA-894A, aimed at treating Charcot-Marie-Tooth disease type 2S (CMT2S). This designation highlights the serious nature of CMT2S, a rare inherited neurological disorder affecting children. The therapy targets a unique genetic variant of the disease, which has limited treatment options available.
Read more →VNDAVanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda Pharmaceuticals has received orphan drug designation from Japan's MHLW for imsidolimab, a monoclonal antibody aimed at treating generalized pustular psoriasis (GPP). This designation offers development incentives and underscores the drug's potential to meet significant unmet medical needs in a rare disease affecting approximately 2,200 individuals in Japan. The designation follows similar recognition in the U.S., highlighting global interest in imsidolimab.
Read more →VNDA▼ -14.1%on this news
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals announced its participation in several investor conferences scheduled for May 2026. These include the Bank of America Securities Global Health Care Conference in Las Vegas, the HCW 4th Annual BioConnect Investor Conference in New York City, and the B. Riley Securities 26th Annual Investor Conference in California. The company aims to connect with investors and showcase its innovative therapies.
Read more →VNDA▼ -14.1%on this newsshared move
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
Vanda Pharmaceuticals reported strong financial results for Q1 2026, showcasing a 26% increase in Fanapt sales and the successful launch of NEREUS. The company also received FDA approval for BYSANTI, contributing to an optimistic revenue outlook for the year. However, Vanda reported a net loss of $48.6 million, raising concerns about financial sustainability amidst ongoing product development.
Read more →VNDA▲ +8%on this newsshared move
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals has announced the commercial availability of NEREUS™ (tradipitant), the first new treatment for motion sickness in over 40 years. This neurokinin-1 receptor antagonist is now accessible via traditional pharmacies and a direct-to-consumer platform. It is aimed at preventing vomiting induced by motion in adults and is priced at $85 per dose, significantly lower than the standard rate. The drug's efficacy was established through pivotal Phase 3 clinical trials, marking a historic advancement in motion sickness management.
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. will release its first quarter 2026 financial results on May 6, 2026, after market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate activities. Investors can access the call via phone or through a webcast on Vanda's website.
Read more →VNDAVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Vanda Pharmaceuticals has announced the publication of a pivotal phase III study on imsidolimab for Generalized Pustular Psoriasis in NEJM Evidence. This study is part of the Biologics License Application submitted to the FDA, with a target action date of December 12, 2026. Imsidolimab is a monoclonal antibody targeting IL-36 receptor signaling, with potential regulatory exclusivity extending into the late 2030s.
Read more →VNDAVanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals has appointed Dr. Charles Duncan to its Board of Directors, effective April 22, 2026. Dr. Duncan, a seasoned leader in the life sciences sector, brings nearly three decades of experience as a biotechnology equity research analyst. His expertise is expected to complement Vanda's efforts in advancing its innovative pipeline and addressing patient needs.
Read more →VNDAVanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
Vanda Pharmaceuticals has urged the FDA to withdraw a proposal from its FY 2027 budget that would extend drug review timelines and replace formal hearings with internal appeals. The company argues that this change would worsen delays and reduce transparency for patients. Vanda's CEO criticized the proposal as a move to legalize slower review processes, which could negatively impact innovation and patient access to medications.
Read more →About Vanda Pharmaceuticals Inc.
Headquarters2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037
BIOPHARMAWATCH ELITE PLUS
Trade the next VNDA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime